SAVA

Cassava Sciences Inc

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025.

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc...

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA Cassava Sciences, Inc. Securities Fraud Class...

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm Lead Plaintiff Deadline on February 10, 2025...

Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff...

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to...

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA Cassava Sciences, Inc. Sued for Securities Law Violations...